Characteristic | Values (N = 75) |
---|---|
Female, % | 98.7 |
Age, years | 36.4 ± 11.9 |
Time since initial PAH diagnosis, months | 49.5 (39.3–69.7) |
BMI, kg/m2 | 22.4 ± 3.4 |
Education | |
Middle school, % | 23.2 |
High school, % | 15.9 |
College, % | 60.9 |
Marital status | |
Married, % | 74.3 |
Unmarried, % | 23.1 |
Divorce,% | 2.6 |
Smoking | |
Yes, % | 1.9 |
No, % | 98.1 |
CTD etiology | |
SLE, % | 56.7 |
SS, % | 15.0 |
SSc, % | 11.8 |
UCTD, % | 8.3 |
RA, % | 1.7 |
Clinical features | |
Arthritis, % | 30.7 |
ILD, % | 10.7 |
WHO functional class | |
I, % | 14.9 |
II, % | 60.9 |
III, % | 24.3 |
NT-proBNP, pg/ml | 95.0 (39.0–390.0) |
Echocardiography | |
PASP, mmHg | 55.9 ± 24.5 |
TAPSE, mm | 18.9 ± 3.7 |
RV diameter, mm | 40.9 ± 6.5 |
RV internal dimension, mm | 24.6 ± 6.7 |
Pericardial effusion, % | 17.7 |
LVEF, % | 68.3 ± 6.9 |
RHC | |
mRAP, mmHg | 8.5 ± 2.9 |
mPAP, mmHg | 38.9 ± 13.7 |
PAWP, mmHg | 11.9 ± 3.6 |
PVR, WU | 4.8 ± 3.1 |
CI, L/(min × m2) | 3.7 ± 0.8 |
Treatment | |
Glucocoticoid | |
High-dose (≥ 40 mg/day), % | 22.7 |
Medium-dose (15 mg/day < x < 40 mg/day), % | 13.3 |
Low-dose (≤ 15 mg/day), % | 64 |
Immunosuppressant | |
CYC, % | 30.5 |
MMF, % | 30.5 |
TAC, % | 40.7 |
HCQ, % | 69.5 |
≥ 2, % | 78.0 |
PAH medication | |
ERA, % | 54.2 |
PDE5-I, % | 55.9 |
PG, % | 3.4 |
≥ 2, % | 16.3 |
Diuretic, % | 66.1 |
Digoxin, % | 37.3 |